Athenex announces a reverse stock split

Buffalo, n.y., feb. 14, 2023 (globe newswire) -- athenex, inc., (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. eastern time on february 15, 2023. beginning tomorrow, february 15, 2023, the company's common stock will trade on a split-adjusted basis.
ATNX Ratings Summary
ATNX Quant Ranking